| Name | Title | Contact Details |
|---|
Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine. Affinivax designs each of its vaccine candidates to optimize the protective immune response to one or both of these antigens utilizing the distinctive plug-and-play nature of its proprietary MAPS™ technology platform, presenting the potential opportunity to make a significant step forward in addressing major healthcare challenges posed by novel and resistant infectious diseases. Affinivax was founded in 2014 with a seed investment from the Bill & Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Children`s Hospital.
Globe Labs Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Silverback Therapeutics is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness — until now.
Manufacturer of diagnostics for global fungal diseases such as, cryptococcosis, aspergillosis, histoplasmosis, coccidioidomycosis (Valley Fever), blastomycosis, and candida.
Perlegen Sciences, Inc. is a Newark, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.